Stock·NYSE·Healthcare
Boston Scientific Corp (BSX)
- Market cap
- $60.82B
- P/E
- 17.71
- Dividend yield
- None
- Street target
- $56.00median of 30 analysts
- 52-week range
- $39.57 $105.65
BSX stock forecast today
Where BSX stands today, and what CleaRank Financial AI makes of it.
BSX at a glance
Boston Scientific Corp (BSX): Hold, 49/100 on CleaRank's AI score.
- Trend Down: the price is below both its 50- and 200-day moving averages ($44.79 and $56.52).
- Earnings BSX beat estimates in 8 of its last 8 quarters, yet fell the next day after 3 of those beats.
- Insiders Insiders sold $90.5M and bought $10.0M over the last 18 months.
- Valuation P/E of 17.7 against 31.9 for the Healthcare sector: a discount to peers (-44%).
Figures as of October 30, 2026.
CleaRank Financial AI
BSX, or Boston Scientific Corp, receives a CleaRank rating of Hold and a model score of 49/100.
Analysts' outlook is the strongest support for that score, with 24 of 30 analysts rating the stock a buy and a median target 33.4% above the price. Trend is the heaviest drag: the price sits 25.74% below the 200-day average and 6.30% below the 50-day average, which itself is 20.74% below the 200-day. Those averages stand at $44.79 and $56.52. Across the past year the price has fallen 58.27%.
Only on CleaRank
Figures we compute ourselves from BSX's own price, earnings and insider-filing history. Tap one to see it in context.
BSX stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
0/4Price below its 50-day average ›
The price of $41.97 is 6.3% below the 50-day simple moving average of $44.79.Price below its 200-day average ›
The price is 25.7% below the 200-day simple moving average of $56.52.50-day average below the 200-day ›
The 50-day average ($44.79) is 20.7% below the 200-day average ($56.52), the arrangement of a falling longer-term trend.In the lower half of its 52-week range ›
The price sits at 4% of its 52-week range, between $39.57 and $105.65.
BSX share price
Pick a period: each tab shows how far BSX has moved over it, to the last close.
Today's trading
Where BSX sits inside today's range and its 52-week range.
BSX fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
4/4P/E below the sector median ›
The trailing P/E of 17.71 is 44.5% below the Healthcare median of 31.9.P/S below the sector median ›
The price-to-sales ratio of 2.89 is 15.1% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $3.5B on revenue of $21.1B, a net margin of 16.6%.Beat estimates in most recent reports ›
BSX beat the EPS estimate in 8 of its last 8 reports.
Key statistics
The headline figures for BSX.
As of October 30, 2026, BSX trades at $41.97, with a market value of $60.82B and a P/E ratio of 17.71.
What the numbers say
CleaRank Financial AI's reading of BSX's valuation, growth and risks.
The trailing P/E of 17.71 puts BSX 44.5% below the Healthcare median P/E of 31.9, a gap the peer comparison on this page labels a discount to peers. On sales, the P/S of 2.89 is 15.0% below the sector median P/S of 3.4. Its market capitalisation stands at $60.8B.
Profitability is strong, though. The company keeps a net margin of 16.62% and an operating margin of 19.05%, and its return on equity of 11.84% sits above the sector median of 7.3%. Debt-to-equity is 0.50.
BSX reported EPS of $0.73 in its most recent earnings release on October 28, 2026, against the $0.72 that analysts had penciled in. That beat the estimate by 1.39%. The shares moved up 0.61% in the following session.
BSX has topped the EPS estimate in all 8 of its last reports, yet the share price fell the next session after 3 of those 8 beats. Analysts expect EPS of $3.24 for this fiscal year and $3.38 for next, which works out to growth of 5.8% for the current year.
BSX's average daily move is 1.82%. The downtrend is itself a risk for as long as the price stays under both moving averages. The price is 60.27% below its 52-week high of $105.65. Over the last 18 months, insider sales totalled $90.5M against $10.0M of purchases; planned sales and tax sales on vesting shares make selling a weaker signal than buying.
BSX against the Healthcare sector
How BSX compares with the median Healthcare stock CleaRank tracks.
Price to earnings vs sector: BSX trades at a notable discount to sector peers (-44%), which may indicate undervaluation or specific company headwinds.
Return vs XLV: Since May 19, 2025, BSX has lost 60.0% against a gain of 37.0% for XLV.
Performance against XLV
BSX and the Healthcare sector fund over the same days.
Revenue and earnings
How much BSX sells, and how much of it becomes profit.
The quarterly bars end with Q2 '26 (the quarter to June 30, 2026); BSX reported again on October 28, 2026, and that quarter is not in our statement data yet. The 12-month figures come from the statistics feed and may include it.
Revenue growth: Revenue grew 19.9% in FY2025 to $20.1B, from $16.7B a year earlier.
Profit margin: The net margin was 14.4% in FY2025, up from 11.0% the year before.
Profitable: BSX earned $2.9B in FY2025.
Earnings reality check
Did BSX beat what analysts expected, and how did the stock react?
Earnings record: BSX beat the analyst estimate in 8 of the last 8 quarters.
Market reaction: The stock fell in the first session after 3 of those 8 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Oct 28, 2026after close | $0.72 | $0.73 | +1.39% | +0.61% | - |
| Jul 29, 2026after close | $0.83 | $0.86 | +3.61% | -0.09% | +3.69% |
| Apr 22, 2026after close | $0.79 | $0.80 | +1.27% | +1.26% | -11.90% |
| Feb 4, 2026after close | $0.78 | $0.80 | +2.56% | +2.83% | -2.69% |
| Oct 22, 2025after close | $0.71 | $0.75 | +5.63% | -1.41% | -3.42% |
| Jul 23, 2025after close | $0.73 | $0.75 | +2.74% | -1.44% | -0.93% |
| Apr 23, 2025after close | $0.67 | $0.75 | +11.94% | +2.24% | +3.99% |
| Feb 5, 2025after close | $0.66 | $0.70 | +6.06% | +0.05% | +0.76% |
As of October 30, 2026, BSX has beaten the analyst EPS estimate in 8 of its last 8 reported quarters and fell in the first trading session after 3 of those beats; its latest report, on October 28, 2026, came in 1.39% above the estimate and the stock moved +0.61% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
BSX AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
1/3RSI not overbought or oversold ›
The 14-day RSI is 38.7, showing bearish momentum without being oversold.RSI below 50 ›
An RSI of 38.7 is below the 50 midpoint, so sellers have had the upper hand over the last 14 days.MACD line below zero ›
The MACD line is negative, so the 12-day average is below the 26-day average.
CleaRank Financial AI analysis of BSX
The score, the reasoning behind it, and what could move the price next.
Boston Scientific Corp (BSX) changes hands at $41.97, leaving it beneath both of its principal moving averages. The stock sits 6.30% under its 50-day average of $44.79 and 25.74% under its 200-day average of $56.52. Sitting at 4% of its 52-week range, the price is 6.07% above the 52-week low of $39.57. Because the 50-day average is 20.74% below the 200-day average, the shorter-term trend is the weaker of the two.
On momentum, the 14-day RSI reads 38.7, in the bearish zone, above the oversold line, with the MACD line negative. The recent returns all show a loss, with the price down 10.19% over the past three months, 25.72% over the past six months and 58.27% over the past year. The price fell 1.69% in the last session on volume 82.5% above its average.
Earnings beat ›
The October 28, 2026 report beat the EPS estimate by 1.39%, and the share price rose 0.61% in the first session after it.
Source: Earnings report, October 28, 2026
Analyst downgrade ›
Citigroup downgraded it to Neutral from Buy on September 17, 2026.
Source: Analyst action, Citigroup, September 17, 2026
New analyst coverage ›
Barclays started coverage at Equal-Weight on October 7, 2026.
Source: Analyst action, Barclays, October 7, 2026
- The two closest levels to keep an eye on are the 20-day EMA at $43.96, which sits above the price, and the 52-week low at $39.57, which sits below it.
- The MACD line is negative and the 14-day RSI reads 38.7, in the bearish zone. Readings above 70 or below 30 signal stretched momentum.
- The share price rose 0.61% in the first session after the October 28, 2026 report. BSX has beaten estimates in 8 of the last 8 reports.
While BSX trades below both its 50-day average of $44.79 and its 200-day average of $56.52, the downtrend is intact. A close back above the 50-day average would be the first sign of a repair. Overhead, the 20-day EMA at $43.96 is the first level the price would have to clear.
The next level below the price is the 52-week low at $39.57. With the RSI in the bearish band, momentum does not currently favour a fast rebound.
Technical indicators
Momentum and trend for BSX, from its daily closes.
As of October 30, 2026, with BSX at $41.97, its 14-day RSI is 38.7 (showing bearish momentum without being oversold), its 50-day simple moving average is $44.79 and its 200-day is $56.52.
Calculated by CleaRank on daily closes as of October 30, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What BSX moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 30, 2026, BSX's 1-year correlation of daily returns is +0.27 with S&P 500 (SPY), +0.20 with Nasdaq 100 (QQQ), -0.02 with Bitcoin (BTC) and +0.03 with gold (XAU).
BSX price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
24 of 30 analysts rate it a buy or strong buy, 6 a hold and 0 a sell.Median target above the price ›
The median 12-month target of $56.00 is 33.4% above the price.No more buy ratings than three months ago ›
24 of 30 rate it a buy now, against 26 of 31 three months ago.
BSX Wall Street View
12-month price targets
The price, $41.97, sits below every analyst's target.
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 14, 2026 | Truist Securities | Maintains | Buy |
| Oct 7, 2026 | Barclays | Initiates | Equal-Weight |
| Oct 5, 2026 | Citigroup | Maintains | Neutral |
| Sep 24, 2026 | Wells Fargo | Maintains | Equal-Weight |
| Sep 21, 2026 | Oppenheimer | Maintains | Outperform |
| Sep 17, 2026 | Citigroup | Downgrade | Neutral |
As of October 30, 2026, 30 Wall Street analysts cover BSX: 24 rate it a buy or strong buy, 6 a hold and 0 a sell or strong sell. Their 12-month price targets range from $44.00 to $78.00. The median BSX price target is $56.00, 33.4% above the price of $41.97.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
BSX trade plan: entry, stop loss and targets
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
BSX trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from BSX's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much BSX tends to move, against the market and on its own.
BSX price history and drawdowns
BSX's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
2/4Average daily move under 2% ›
The price has moved 1.82% on an average day (30-day standard deviation of daily returns).Not yet recovered from its worst fall ›
The worst fall was 61.5%, from September 2025 to October 2026; the price is still 61.2% below that peak.Most 1-year holds ended higher ›
75% of 1-year holding periods in the last 10 years ended with a gain.Trailed the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $19,405, against $42,358 in the S&P 500 (SPY).
BSX Drawdowns & Recovery
As of October 30, 2026, BSX's worst peak-to-trough fall over the last 10 years with dividends reinvested was -61.5% (September 2025 to October 2026); it is still 61.2% below that peak, and 75% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into BSX in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: BSX trailed the S&P 500 over this period: $19,405 against $42,358.
A $10,000 investment in BSX in October 2016 would be worth about $19,405 today with dividends reinvested, compared with about $42,358 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to BSX, and which have not.
Strongest month, January: an average of +6.82%, up in 7 of 10 years.
Weakest month, March: an average of -4.32%, up in 3 of 10 years.
This month, October: has averaged -0.63%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, BSX's strongest calendar month has been January (average +6.82%, up in 7 of 10 years) and its weakest March (average -4.32%, up in 3 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
BSX stock price prediction 2030
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in BSX, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 4-year Monte Carlo simulation, based on 10 years of price history, projects that a $10,000 investment in BSX today could grow to about $12,880 by 2030 in the base case, with a 90th-percentile outcome near $26,467 and a 10th-percentile outcome around $6,268. Projections are statistical simulations, not guarantees.
BSX Stock Price Prediction 2030: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $54.06 for BSX by 2030 in the base case, from $41.97 today (1.3x over 4 years). The 10th-percentile path ends near $26.31. These are outcomes of a Monte Carlo simulation run on BSX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $31.19 | $44.71 | $64.09 | |
| 2028 | $28.62 | $47.63 | $79.26 | |
| 2029 | $27.19 | $50.74 | $94.68 | |
| 2030 | $26.31 | $54.06 | $111 |
Method: a lognormal simulation of BSX's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
BSX insider trading
What the people running the company have bought and sold.
BSX insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: Insiders bought $10.0M on the open market and sold $90.5M.
As of October 30, 2026, BSX insiders reported 19 open-market sales worth $90.5M and 8 open-market purchases worth $10.0M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 2, 2026 | Padraig Andrew O'Connor
Officer
|
Grant | 1.2K | - |
| Aug 25, 2026 | Susan E. Morano
Director
|
Buy | 2.0K | $100.4K |
| Aug 5, 2026 | David C Habiger
Director
|
Buy | 2.1K | $99.9K |
| Aug 4, 2026 | David C Habiger
Director
|
Buy | 1.2K | $56.9K |
| Aug 3, 2026 | Michael F Mahoney
Chief Executive Officer
|
Buy | 186.2K | $9.0M |
| Jul 31, 2026 | Edward J. Ludwig
Director
|
Buy | 5.0K | $227.4K |
| Jul 1, 2026 | Jonathan R Monson
Chief Financial Officer
|
Grant | 2.1K | - |
| May 28, 2026 | Michael F Mahoney
Chief Executive Officer
|
Grant | 386.8K | - |
| May 20, 2026 | David C Habiger
Director
|
Buy | 4.5K | $251.1K |
| May 20, 2026 | Edward J. Ludwig
Director
|
Buy | 3.6K | $202.9K |
| May 20, 2026 | Cheryl Pegus
Director
|
Buy | 1.8K | $100.0K |
| May 7, 2026 | David C Habiger
Director
|
Grant | 3.8K | - |
| May 7, 2026 | Edward J. Ludwig
Director
|
Grant | 3.8K | - |
| May 7, 2026 | Jessica L Mega, M.D.
Director
|
Grant | 3.8K | - |
| May 7, 2026 | Susan E. Morano
Director
|
Grant | 5.1K | - |
| May 7, 2026 | Christophe Pierre Weber
Director
|
Grant | 2.9K | - |
| May 7, 2026 | David S Wichmann
Director
|
Grant | 3.8K | - |
| May 7, 2026 | Ellen M Zane
Director
|
Grant | 3.8K | - |
| May 1, 2026 | Arthur C Butcher
Officer
|
Grant | 2.1K | - |
| May 1, 2026 | Padraig Andrew O'Connor
Officer
|
Grant | 1.8K | - |
| Mar 2, 2026 | Susan E. Morano
Director
|
Grant | 24 | - |
| Mar 2, 2026 | Christophe Pierre Weber
Director
|
Grant | 879 | - |
| Feb 27, 2026 | Emily Woodworth
Officer
|
Grant | 838 | - |
| Feb 13, 2026 | Vance R Brown
General Counsel
|
Grant | 4.8K | - |
| Feb 13, 2026 | Vance R Brown
General Counsel
|
Grant | 29.6K | - |
| Feb 13, 2026 | Arthur C Butcher
Officer
|
Grant | 8.0K | - |
| Feb 13, 2026 | Arthur C Butcher
Officer
|
Grant | 50.8K | - |
| Feb 13, 2026 | Joseph Michael Fitzgerald
Officer
|
Grant | 69.8K | - |
| Feb 13, 2026 | Joseph Michael Fitzgerald
Officer
|
Grant | 11.1K | - |
| Feb 13, 2026 | Michael F Mahoney
Chief Executive Officer
|
Grant | 264.4K | - |
| Feb 13, 2026 | Michael F Mahoney
Chief Executive Officer
|
Grant | 41.6K | - |
| Feb 13, 2026 | Jonathan R Monson
Chief Financial Officer
|
Grant | 3.8K | - |
| Feb 13, 2026 | Padraig Andrew O'Connor
Officer
|
Grant | 2.6K | - |
| Feb 13, 2026 | Miriam O'Sullivan
Officer
|
Grant | 2.7K | - |
| Feb 13, 2026 | Emily Woodworth
Officer
|
Grant | 2.7K | - |
| Feb 12, 2026 | Vance R Brown
General Counsel
|
Grant | 1.4K | - |
| Feb 12, 2026 | Arthur C Butcher
Officer
|
Grant | 2.7K | - |
| Feb 12, 2026 | Joseph Michael Fitzgerald
Officer
|
Grant | 3.5K | - |
| Feb 12, 2026 | Michael F Mahoney
Chief Executive Officer
|
Grant | 13.7K | - |
| Feb 12, 2026 | Jonathan R Monson
Chief Financial Officer
|
Grant | 1.2K | - |
| Feb 12, 2026 | Padraig Andrew O'Connor
Officer
|
Grant | 1.1K | - |
| Feb 12, 2026 | Miriam O'Sullivan
Officer
|
Grant | 961 | - |
| Feb 12, 2026 | Emily Woodworth
Officer
|
Grant | 481 | - |
| Feb 2, 2026 | Michael F Mahoney
Chief Executive Officer
|
Sell | 160.9K | $15.0M |
| Feb 2, 2026 | Michael F Mahoney
Chief Executive Officer
|
Option | 95.8K | $2.5M |
| Dec 1, 2025 | Arthur C Butcher
Officer
|
Sell | 17.3K | $1.8M |
| Dec 1, 2025 | Arthur C Butcher
Officer
|
Option | 17.3K | $429.5K |
| Nov 28, 2025 | Miriam O'Sullivan
Officer
|
Grant | 260 | - |
| Nov 14, 2025 | Joseph Michael Fitzgerald
Officer
|
Grant | 10.3K | - |
| Nov 6, 2025 | Ellen M Zane
Director
|
Sell | 12.9K | $1.3M |
| Nov 3, 2025 | Joseph Michael Fitzgerald
Officer
|
Sell | 50.0K | $5.0M |
| Nov 3, 2025 | Joseph Michael Fitzgerald
Officer
|
Option | 50.0K | $1.3M |
| Oct 30, 2025 | Michael F Mahoney
Chief Executive Officer
|
Grant | 150.0K | - |
| Oct 28, 2025 | Ellen M Zane
Director
|
Sell | 12.9K | $1.3M |
| Oct 1, 2025 | Joseph Michael Fitzgerald
Officer
|
Sell | 50.0K | $4.9M |
| Oct 1, 2025 | Joseph Michael Fitzgerald
Officer
|
Option | 50.0K | $1.3M |
| Sep 2, 2025 | Joseph Michael Fitzgerald
Officer
|
Sell | 50.0K | $5.3M |
| Sep 2, 2025 | Joseph Michael Fitzgerald
Officer
|
Option | 50.0K | $1.3M |
| Aug 1, 2025 | Joseph Michael Fitzgerald
Officer
|
Sell | 50.0K | $5.2M |
| Aug 1, 2025 | Arthur C Butcher
Officer
|
Sell | 17.3K | $1.8M |
| Aug 1, 2025 | Arthur C Butcher
Officer
|
Option | 17.3K | $429.5K |
| Aug 1, 2025 | Joseph Michael Fitzgerald
Officer
|
Option | 50.0K | $1.3M |
| Aug 1, 2025 | Edward J. Ludwig
Director
|
Grant | 500 | - |
| Aug 1, 2025 | Jonathan R Monson
Chief Financial Officer
|
Grant | 1.1K | - |
| Jul 29, 2025 | Yoshiaki Fujimori
Director
|
Sell | 2.9K | $310.4K |
| Jul 25, 2025 | Edward J. Ludwig
Director
|
Sell | 4.0K | $424.1K |
| Jul 1, 2025 | Joseph Michael Fitzgerald
Officer
|
Sell | 50.0K | $5.3M |
| Jul 1, 2025 | Vance R Brown
General Counsel
|
Grant | 4.0K | - |
| Jul 1, 2025 | Joseph Michael Fitzgerald
Officer
|
Option | 50.0K | $1.3M |
| Jun 4, 2025 | Joseph Michael Fitzgerald
President
|
Sell | 56.4K | $5.8M |
| Jun 4, 2025 | Joseph Michael Fitzgerald
President
|
Option | 56.4K | $1.5M |
| Jun 2, 2025 | Michael F Mahoney
Chief Executive Officer
|
Sell | 164.4K | $17.1M |
| Jun 2, 2025 | Michael F Mahoney
Chief Executive Officer
|
Option | 105.6K | $2.2M |
| May 29, 2025 | Edward J. Ludwig
Director
|
Sell | 4.0K | $418.4K |
| May 21, 2025 | Vance R Brown
General Counsel
|
Sell | 4.8K | $513.6K |
| May 8, 2025 | Yoshiaki Fujimori
Director
|
Grant | 2.1K | - |
| May 8, 2025 | David C Habiger
Director
|
Grant | 2.1K | - |
| May 8, 2025 | Edward J. Ludwig
Director
|
Grant | 2.1K | - |
| May 8, 2025 | Jessica L Mega, M.D.
Director
|
Grant | 2.1K | - |
| May 8, 2025 | Susan E. Morano
Director
|
Grant | 2.7K | - |
| May 8, 2025 | John E Sununu
Director
|
Grant | 2.1K | - |
| May 8, 2025 | David S Wichmann
Director
|
Grant | 2.1K | - |
| May 8, 2025 | Ellen M Zane
Director
|
Grant | 2.1K | - |
| May 5, 2025 | John Bradley Sorenson
Officer
|
Sell | 4.6K | $478.0K |
| May 2, 2025 | Arthur C Butcher
Officer
|
Grant | 2.1K | - |
| May 2, 2025 | John Bradley Sorenson
Officer
|
Grant | 4.2K | - |
| May 1, 2025 | Michael F Mahoney
Chief Executive Officer
|
Sell | 164.4K | $16.9M |
| May 1, 2025 | Arthur C Butcher
Officer
|
Sell | 17.3K | $1.8M |
| May 1, 2025 | Arthur C Butcher
Officer
|
Option | 17.3K | $429.5K |
| May 1, 2025 | Michael F Mahoney
Chief Executive Officer
|
Option | 105.6K | $2.2M |
Source: TwelveData, from SEC Form 4 filings
BSX stock forecast: questions people ask
Answered from the figures on this page, as of October 30, 2026.